EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cinobufagin Directly Targets PDE4D to Disrupt Fibroblast–Dendritic Cell Crosstalk in Atopic Dermatitis

Shicong Li, Dihui Xu, Chenyang Zhang, Chunxiu Xiao, Meng Yu, Jiaojiao Wang, Wenyuan Wu, Xiang Lv, Dongping Yuan, Liang Zhang, Min Hong, Jing Zhou und 3 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202501670 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Shicong Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, and Jiangsu Key Laboratory for High Technology Research of …. Hauptthemen laut MEDLINE: Bufanolides, Cyclic Nucleotide Phosphodiesterases, Type 4, Fibroblasts, Dermatitis, Atopic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Natural Science Foundation of Nanjing University of Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a chronic inflammatory skin disease driven by immune dysregulation and Th2‐dominant inflammation. This study identifies phosphodiesterase 4D (PDE4D) as a key regulator of AD pathogenesis and a potential therapeutic target. Single‐cell RNA sequencing (scRNA‐seq) revealed activation of the macrophage migration inhibitory factor (MIF) signaling pathway in lesional tissues, with inflammatory fibroblasts mediating MIF‐driven interactions with myeloid cells. Elevated PDE4D expression in lesional tissues suppressed cyclic adenosine monophosphate (cAMP) signaling, promoting inflammation. Cinobufagin, a bufadienolide compound, is identified as a potent PDE4D inhibitor. Compared to other PDE4 inhibitors used in clinical cases, cinobufagin demonstrated superior efficacy in improving AD in mice while effectively regulating the MIF pathway. It directly bound to PDE4D, restored cAMP signaling, suppressed MIF secretion in inflammatory fibroblasts, and disrupted fibroblast–dendritic cell interactions via the cAMP/protein kinase A (PKA)/cAMP‐response element binding protein (CREB) pathway, thereby significantly reducing the clinical and histological features of AD. Notably, PDE4D knockout mice exhibited diminished inflammation, mimicking the effects of cinobufagin and confirming a role for PDE4D in AD progression. These findings establish PDE4D as a critical driver of AD and demonstrate that cinobufagin effectively targets this pathway, offering a promising therapeutic approach for AD and related inflammatory skin disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BufanolidesCyclic Nucleotide Phosphodiesterases, Type 4FibroblastsDermatitis, AtopicDendritic CellsAnimalsMiceSignal TransductionMacrophage Migration-Inhibitory FactorsHumansDisease Models, AnimalPhosphodiesterase 4 InhibitorsMice, Inbred C57BL

Stichwörter der Autor:innen

MIFPDE4Datopic dermatitiscinobufaginfibroblast

Substanzen

BufanolidesCyclic Nucleotide Phosphodiesterases, Type 4cinobufaginMacrophage Migration-Inhibitory FactorsPhosphodiesterase 4 Inhibitors

Autor:innen und Institutionen

  • Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, and Jiangsu Key Laboratory for High Technology Research of TCM Formulae, College of Pharmacy, Nanjing University of Chinese Medic…
  • State Key Laboratory of Pharmaceutical Biotechnology and Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, School of Life Sciences, Nan…
  • Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China.

ORCID-Profile: Yuyu Zhu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Natural Science Foundation of Nanjing University of Chinese Medicine
  • Open Project of Chinese Materia Medica First-Class Discipline of Nanjing University of Chinese Medicine

Zitieren

APA

Li, S., Xu, D., Zhang, C., Xiao, C., Yu, M., Wang, J., Wu, W., Lv, X., Yuan, D., Zhang, L., Hong, M., Zhou, J., Sun, Y., Ma, H., & Zhu, Y. (2025). Cinobufagin Directly Targets PDE4D to Disrupt Fibroblast–Dendritic Cell Crosstalk in Atopic Dermatitis. Advanced Science. https://doi.org/10.1002/advs.202501670

Vancouver

Li S, Xu D, Zhang C, Xiao C, Yu M, Wang J, et al. Cinobufagin Directly Targets PDE4D to Disrupt Fibroblast–Dendritic Cell Crosstalk in Atopic Dermatitis. Advanced Science. 2025. doi:10.1002/advs.202501670

BibTeX
@article{Li2025,
  author = {Li, Shicong and Xu, Dihui and Zhang, Chenyang and Xiao, Chunxiu and Yu, Meng and Wang, Jiaojiao and Wu, Wenyuan and Lv, Xiang and Yuan, Dongping and Zhang, Liang and Hong, Min and Zhou, Jing and Sun, Yang and Ma, Hongyue and Zhu, Yuyu},
  title = {Cinobufagin Directly Targets PDE4D to Disrupt Fibroblast–Dendritic Cell Crosstalk in Atopic Dermatitis},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202501670}
}
Kostenlos starten →